Investing.com-- Shares of WuXi AppTec Co (HK: 2359 ) (SS: 603259 ) jumped on Tuesday after the Chinese pharmaceutical services firm reported a substantial 89.1% year-on-year increase in first-quarter net profit, signaling resilience amid global trade uncertainties.

The company on Monday posted net profit attributable to shareholders of 3.67 billion yuan ($507 million) for the January-March period, up from 1.94 billion yuan a year earlier.

Revenue rose 21% to 9.65 billion yuan.

Hong Kong-listed shares of the company jumped 5.5% to HK$61.40 as of 06:34 GMT, reaching their highest level since March 13.

The jump was driven by robust demand for its small molecule drug manufacturing and strong revenue growth in its TIDES (oligonucleotide and peptide) business, which jumped 188% year-on-year.

The robust earnings suggest that WuXi AppTec’s diversified global operations and integrated service model can mitigate the impact of international tariffs. The company’s continued investment in research and development, along with its expansive customer base, underscores its strong market position.